Can treating the SYK cell cure leukemia?
Targeted therapy has remained elusive for most acute myeloid leukemia patients. In this issue of Cancer Cell, Stegmaier and colleagues identify SYK as a key mediator of the differentiation block seen in this disease. Their data suggest that SYK inhibition may be an effective therapy for a significant proportion of AMLs.
Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. james.downing@stjude.org
James R
JR
Downing
D000631:Aminopyridines; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D000077156:Gefitinib; D015973:Gene Expression Regulation, Leukemic; D023281:Genomics / Q000379:methods; D006801:Humans; D020128:Inhibitory Concentration 50; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D009025:Morpholines; D010078:Oxazines / Q000494:pharmacology; D010766:Phosphorylation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D040901:Proteomics / Q000379:methods; D011725:Pyridines / Q000494:pharmacology; D011743:Pyrimidines; D011799:Quinazolines / Q000494:pharmacology; D000072377:Syk Kinase; D013997:Time Factors; D014443:Tyrosine
D000631:Aminopyridines; D000970:Antineoplastic Agents; D047908:Intracellular Signaling Peptides and Proteins; D009025:Morpholines; D010078:Oxazines; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011743:Pyrimidines; D011799:Quinazolines; D014443:Tyrosine; D011505:Protein-Tyrosine Kinases; C000606896:SYK protein, human; D000072377:Syk Kinase; D000077156:Gefitinib; C523665:fostamatinib